Literature DB >> 16981898

Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma.

Sreeja Sudhakaran1, Craig R Rayner, Jian Li, David C M Kong, Neil M Gude, Roger L Nation.   

Abstract

AIMS: To determine whether lower umbilical cord than maternal binding of indinavir and saquinavir contributed to the low cord : maternal (C : M) total concentration ratios reported previously.
METHODS: Indinavir and saquinavir unbound fraction (fu) was determined using equilibrium dialysis. Buffer solutions of human serum albumin (HSA) (20.0, 30.0, 40.0 g l(-1)) and alpha(1)-acid glycoprotein (AAG) (0.20, 0.60, 2.00 g l(-1)) were spiked with indinavir (1.00 and 8.00 mg l(-1)) or saquinavir (0.15 and 1.50 mg l(-1)). Matched maternal and umbilical cord plasma was spiked with 1.00 mg l(-1) indinavir (n = 12) or 0.15 mg l(-1) saquinavir (n = 20). Spiked protein/plasma solutions were dialyzed against isotonic phosphate buffer, at 37 degrees C. At equilibrium, indinavir and saquinavir concentrations were quantified, and the f(u) determined.
RESULTS: Indinavir and saquinavir demonstrated protein concentration-dependent binding in buffer solutions of HSA and AAG. Indinavir f(u) was significantly higher in umbilical cord (0.53 +/- 0.12) compared with maternal (0.36 +/- 0.11) plasma (95% CI of the difference -0.26, -0.097). Similarly, saquinavir fu was different between umbilical cord (0.0090 +/- 0.0046) and maternal plasma (0.0066 +/- 0.0039) (95% CI of the difference -0.0032, -0.0016). The transplacental AAG concentration gradient contributed significantly to the binding differential of both drugs.
CONCLUSIONS: The differential plasma binding of both drugs, which was largely the result of the transplacental AAG concentration gradient, would contribute to the low C : M total plasma concentration ratios observed previously. Unbound concentrations of indinavir and saquinavir are likely to be substantially lower in umbilical cord than maternal plasma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16981898      PMCID: PMC2000742          DOI: 10.1111/j.1365-2125.2006.02766.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  32 in total

Review 1.  Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.

Authors:  M T Huisman; J W Smit; A H Schinkel
Journal:  AIDS       Date:  2000-02-18       Impact factor: 4.177

Review 2.  HIV-1 protease inhibitors.

Authors:  J J Eron
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

3.  The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.

Authors:  Rolf P G van Heeswijk; Yasmin Khaliq; Keith D Gallicano; Marc Bourbeau; Isabelle Seguin; Elizabeth J Phillips; D William Cameron
Journal:  Clin Pharmacol Ther       Date:  2004-12       Impact factor: 6.875

4.  Differential bidirectional transfer of indinavir in the isolated perfused human placenta.

Authors:  Sreeja Sudhakaran; Hany Ghabrial; Roger L Nation; David C M Kong; Neil M Gude; Peter W Angus; Craig R Rayner
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 5.  Drug disposition in mother and foetus.

Authors:  D J Morgan
Journal:  Clin Exp Pharmacol Physiol       Date:  1997-11       Impact factor: 2.557

6.  Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.

Authors:  J W Smit; M T Huisman; O van Tellingen; H R Wiltshire; A H Schinkel
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

7.  HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

Authors:  C G Lee; M M Gottesman; C O Cardarelli; M Ramachandra; K T Jeang; S V Ambudkar; I Pastan; S Dey
Journal:  Biochemistry       Date:  1998-03-17       Impact factor: 3.162

8.  Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus.

Authors:  A Molla; S Vasavanonda; G Kumar; H L Sham; M Johnson; B Grabowski; J F Denissen; W Kohlbrenner; J J Plattner; J M Leonard; D W Norbeck; D J Kempf
Journal:  Virology       Date:  1998-10-25       Impact factor: 3.616

9.  Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters.

Authors:  R V Srinivas; D Middlemas; P Flynn; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Drug distribution in whole blood of mothers and their newborn infants: studies of cloxacillin and flucloxacillin.

Authors:  L Herngren; M Ehrnebo; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more
  10 in total

1.  Concentration-effect and dose-response relations in clinical pharmacology.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-03       Impact factor: 4.335

2.  Implications of gender and pregnancy for antiretroviral drug dosing.

Authors:  Brookie M Best; Edmund V Capparelli
Journal:  Curr Opin HIV AIDS       Date:  2008-05       Impact factor: 4.283

3.  Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.

Authors:  C Vinot; L Gavard; J M Tréluyer; S Manceau; E Courbon; J M Scherrmann; X Declèves; D Duro; G Peytavin; L Mandelbrot; C Giraud
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

4.  (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy.

Authors:  Andrea L Gordon; Olga V Lopatko; Andrew A Somogyi; David J R Foster; Jason M White
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

5.  Binding of lopinavir to human alpha1-acid glycoprotein and serum albumin.

Authors:  Abhishek Gulati; F Douglas Boudinot; Phillip M Gerk
Journal:  Drug Metab Dispos       Date:  2009-05-13       Impact factor: 3.922

Review 6.  Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy.

Authors:  Abhishek Gulati; Phillip M Gerk
Journal:  J Pharm Sci       Date:  2009-07       Impact factor: 3.534

Review 7.  Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.

Authors:  Shelley A McCormack; Brookie M Best
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447

8.  Clinical therapeutics in pregnancy.

Authors:  Maisa N Feghali; Donald R Mattison
Journal:  J Biomed Biotechnol       Date:  2011-07-06

9.  Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model.

Authors:  Pierre-Francois Ceccaldi; Laurent Gavard; Laurent Mandelbrot; Elisabeth Rey; Robert Farinotti; Jean-Marc Treluyer; Sophie Gil
Journal:  Obstet Gynecol Int       Date:  2009-05-18

10.  Canine orosomucoid (alpha-1 acid glycoprotein) variants and their influence on drug plasma protein binding.

Authors:  Ana P Costa; Michael H Court; Nicolas F Villarino; Neal S Burke; Katrina L Mealey
Journal:  J Vet Pharmacol Ther       Date:  2020-08-03       Impact factor: 1.786

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.